JP2002053555A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002053555A5 JP2002053555A5 JP2001164523A JP2001164523A JP2002053555A5 JP 2002053555 A5 JP2002053555 A5 JP 2002053555A5 JP 2001164523 A JP2001164523 A JP 2001164523A JP 2001164523 A JP2001164523 A JP 2001164523A JP 2002053555 A5 JP2002053555 A5 JP 2002053555A5
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- adamantyl
- pyridyl
- propyl
- urea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(C)(C)OC(N(C)C*)=O Chemical compound CC(C)(C)OC(N(C)C*)=O 0.000 description 1
Description
【特許請求の範囲】
【請求項1】 ・1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[3−(4−ピリジル)プロピル]ウレア、
・1−[2−(1−アダマンチル)エチル]−3−[3−(4−ピリジル)プロピル]−1−(3,3,3−トリフルオロプロピル)ウレア、
・1−[2−(1−アダマンチル)エチル]−1−(2−ブテニル)−3−[3−(4−ピリジル)プロピル]ウレア、
・1−[2−(1−アダマンチル)エチル]−1−[2−[N−(t−ブトキシカルボニル)−N−メチルアミノ]エチル]−3−[3−(4−ピリジル)プロピル]ウレア、
・1−[3−(1−アダマンチル)プロピル]−1−プロピル−3−[3−(4−ピリジル)プロピル]ウレア、
・(Z)−1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[3−(4−ピリジル)−2−プロペニル]ウレア、
・(−)−1−[2−(1−アダマンチル)エチル]−3−[2−メチル−3−(4−ピリジル)プロピル]−1−ペンチルウレア、
・1−[2−(1−アダマンチル)エチル]−3−[1−メチル−3−(4−ピリジル)プロピル]−1−ペンチルウレア、
・(+)−1−[2−(1−アダマンチル)エチル]−1−[2−[N−(t−ブトキシカルボニル)−N−メチルアミノ]エチル]−3−[2−メチル−3−(4−ピリジル)プロピル]ウレア、
・5−(4−ピリジル)吉草酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド、
・3−(4−ピリジルメチルチオ)プロピオン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド、
・2−[2−(4−ピリジル)エチルチオ]酢酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド、
・6−(4−ピリジル)カプロン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド、
・cis−1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[2−(4−ピリジル)シクロプロピルメチル]ウレア
・1−[2−(1−アダマンチル)エチル]−3−[2−メチル−3−(4−ピリジル)プロピル]−1−ペンチルウレア、
・1−[2−(1−アダマンチル)エチル]−1−[2−[N−(t−ブトキシカルボニル)−N−メチルアミノ]エチル]−3−[2−メチル−3−(4−ピリジル)プロピル]ウレア、
・(E)−1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[3−(4−ピリジル)−2−プロペニル]ウレアおよび
・(+)−1−[2−(1−アダマンチル)エチル]−3−[2−メチル−3−(4−ピリジル)プロピル]−1−ペンチルウレア
よりなる群から選ばれる化合物またはその塩類。
【請求項2】 請求項1に記載の化合物またはその塩類を有効成分として含有する医薬組成物。
【請求項3】 請求項1に記載の化合物またはその塩類を有効成分として含有するTNF−α産生阻害剤。
【請求項4】 請求項1に記載の化合物またはその塩類を有効成分として含有する自己免疫性疾患治療剤。
【請求項5】 請求項1に記載の化合物またはその塩類を有効成分として含有する抗リウマチ剤。
【請求項1】 ・1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[3−(4−ピリジル)プロピル]ウレア、
・1−[2−(1−アダマンチル)エチル]−3−[3−(4−ピリジル)プロピル]−1−(3,3,3−トリフルオロプロピル)ウレア、
・1−[2−(1−アダマンチル)エチル]−1−(2−ブテニル)−3−[3−(4−ピリジル)プロピル]ウレア、
・1−[2−(1−アダマンチル)エチル]−1−[2−[N−(t−ブトキシカルボニル)−N−メチルアミノ]エチル]−3−[3−(4−ピリジル)プロピル]ウレア、
・1−[3−(1−アダマンチル)プロピル]−1−プロピル−3−[3−(4−ピリジル)プロピル]ウレア、
・(Z)−1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[3−(4−ピリジル)−2−プロペニル]ウレア、
・(−)−1−[2−(1−アダマンチル)エチル]−3−[2−メチル−3−(4−ピリジル)プロピル]−1−ペンチルウレア、
・1−[2−(1−アダマンチル)エチル]−3−[1−メチル−3−(4−ピリジル)プロピル]−1−ペンチルウレア、
・(+)−1−[2−(1−アダマンチル)エチル]−1−[2−[N−(t−ブトキシカルボニル)−N−メチルアミノ]エチル]−3−[2−メチル−3−(4−ピリジル)プロピル]ウレア、
・5−(4−ピリジル)吉草酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド、
・3−(4−ピリジルメチルチオ)プロピオン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド、
・2−[2−(4−ピリジル)エチルチオ]酢酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド、
・6−(4−ピリジル)カプロン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド、
・cis−1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[2−(4−ピリジル)シクロプロピルメチル]ウレア
・1−[2−(1−アダマンチル)エチル]−3−[2−メチル−3−(4−ピリジル)プロピル]−1−ペンチルウレア、
・1−[2−(1−アダマンチル)エチル]−1−[2−[N−(t−ブトキシカルボニル)−N−メチルアミノ]エチル]−3−[2−メチル−3−(4−ピリジル)プロピル]ウレア、
・(E)−1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[3−(4−ピリジル)−2−プロペニル]ウレアおよび
・(+)−1−[2−(1−アダマンチル)エチル]−3−[2−メチル−3−(4−ピリジル)プロピル]−1−ペンチルウレア
よりなる群から選ばれる化合物またはその塩類。
【請求項2】 請求項1に記載の化合物またはその塩類を有効成分として含有する医薬組成物。
【請求項3】 請求項1に記載の化合物またはその塩類を有効成分として含有するTNF−α産生阻害剤。
【請求項4】 請求項1に記載の化合物またはその塩類を有効成分として含有する自己免疫性疾患治療剤。
【請求項5】 請求項1に記載の化合物またはその塩類を有効成分として含有する抗リウマチ剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001164523A JP3867196B2 (ja) | 2000-05-31 | 2001-05-31 | TNF−α産生阻害物質 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-162945 | 2000-05-31 | ||
JP2000162945 | 2000-05-31 | ||
JP2001164523A JP3867196B2 (ja) | 2000-05-31 | 2001-05-31 | TNF−α産生阻害物質 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006140241A Division JP4482735B2 (ja) | 2000-05-31 | 2006-05-19 | TNF−α産生阻害物質 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2002053555A JP2002053555A (ja) | 2002-02-19 |
JP2002053555A5 true JP2002053555A5 (ja) | 2006-07-20 |
JP3867196B2 JP3867196B2 (ja) | 2007-01-10 |
Family
ID=18666780
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001164523A Expired - Fee Related JP3867196B2 (ja) | 2000-05-31 | 2001-05-31 | TNF−α産生阻害物質 |
JP2006140241A Expired - Fee Related JP4482735B2 (ja) | 2000-05-31 | 2006-05-19 | TNF−α産生阻害物質 |
JP2009283085A Pending JP2010059205A (ja) | 2000-05-31 | 2009-12-14 | TNF−α産生阻害物質 |
JP2009283084A Pending JP2010059204A (ja) | 2000-05-31 | 2009-12-14 | TNF−α産生阻害物質 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006140241A Expired - Fee Related JP4482735B2 (ja) | 2000-05-31 | 2006-05-19 | TNF−α産生阻害物質 |
JP2009283085A Pending JP2010059205A (ja) | 2000-05-31 | 2009-12-14 | TNF−α産生阻害物質 |
JP2009283084A Pending JP2010059204A (ja) | 2000-05-31 | 2009-12-14 | TNF−α産生阻害物質 |
Country Status (15)
Country | Link |
---|---|
US (5) | US7098226B2 (ja) |
EP (4) | EP1743885B1 (ja) |
JP (4) | JP3867196B2 (ja) |
KR (2) | KR100978304B1 (ja) |
CN (3) | CN1324012C (ja) |
AT (4) | ATE374186T1 (ja) |
AU (3) | AU6067401A (ja) |
CA (2) | CA2409741C (ja) |
CY (1) | CY1107089T1 (ja) |
DE (4) | DE60130658T2 (ja) |
DK (1) | DK1302461T3 (ja) |
ES (4) | ES2284138T3 (ja) |
NO (2) | NO324472B1 (ja) |
PT (1) | PT1302461E (ja) |
WO (1) | WO2001092229A1 (ja) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1743885B1 (en) * | 2000-05-31 | 2009-11-11 | Santen Pharmaceutical Co., Ltd. | 1-[(adamantyl)alkyl]-3-[(pyridinyl)alkyl]urea compounds as TNF-.alpha inhibitors useful for autoimmune diseases |
CA2468704C (en) * | 2001-11-30 | 2011-06-14 | Santen Pharmaceutical Co., Ltd. | Urea derivatives as angiogenesis inhibitors |
CA2478183C (en) * | 2002-03-12 | 2010-02-16 | Merck & Co. Inc. | Substituted amides |
US7456222B2 (en) | 2002-05-17 | 2008-11-25 | Sequella, Inc. | Anti tubercular drug: compositions and methods |
US20040033986A1 (en) | 2002-05-17 | 2004-02-19 | Protopopova Marina Nikolaevna | Anti tubercular drug: compositions and methods |
CN101404986B (zh) | 2002-05-17 | 2011-09-28 | 赛奎拉公司 | 用于诊断和治疗感染性疾病的组合物和制药方法 |
WO2005034857A2 (en) | 2003-09-05 | 2005-04-21 | Sequella, Inc. | Methods and compositions comprising diamines as new anti-tubercular therapeutics |
WO2005102331A1 (ja) * | 2004-04-27 | 2005-11-03 | Santen Pharmaceutical Co., Ltd. | 骨粗鬆症治療剤 |
WO2005102332A1 (ja) * | 2004-04-27 | 2005-11-03 | Santen Pharmaceutical Co., Ltd. | 変形性関節症治療剤 |
UA87854C2 (en) * | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
WO2006035760A1 (ja) * | 2004-09-27 | 2006-04-06 | Santen Pharmaceutical Co., Ltd. | 皮膚疾患治療剤 |
WO2006035759A1 (ja) * | 2004-09-27 | 2006-04-06 | Santen Pharmaceutical Co., Ltd. | 呼吸器疾患治療剤 |
WO2006043518A1 (ja) * | 2004-10-18 | 2006-04-27 | Santen Pharmaceutical Co., Ltd. | 神経疾患治療剤 |
EP2835367A1 (en) * | 2005-01-05 | 2015-02-11 | AbbVie Inc. | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
KR101496206B1 (ko) * | 2005-01-05 | 2015-02-27 | 애브비 인코포레이티드 | 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제로서의 아다만틸 유도체 |
US20090192198A1 (en) | 2005-01-05 | 2009-07-30 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US8562629B2 (en) * | 2006-10-24 | 2013-10-22 | Arthrocare Corporation | Suture device having selective needle actuation and related method |
EP1935420A1 (en) | 2006-12-21 | 2008-06-25 | Merck Sante | 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors |
WO2009020603A2 (en) * | 2007-08-08 | 2009-02-12 | The Scripps Research Institute | Upp amphiphilic alpha-helix mimetics |
CN101827816B (zh) * | 2007-10-16 | 2013-05-08 | 参天制药株式会社 | Trpv1介导性疾病治疗剂 |
CA2739882A1 (en) * | 2008-10-22 | 2010-04-29 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical composition improving intestinal absorption |
HRP20090186A2 (hr) | 2009-03-31 | 2010-10-31 | Institut Ruđer Bošković | Adamantanski bisureidni derivati, metoda priprave i primjena u detekciji aniona |
KR101231412B1 (ko) * | 2009-12-29 | 2013-02-07 | 실트로닉 아게 | 실리콘 웨이퍼 및 그 제조 방법 |
KR20160110357A (ko) | 2013-11-15 | 2016-09-21 | 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 | Ebna1 억제제 및 그의 사용 방법 |
MX2017014550A (es) | 2015-05-14 | 2018-02-26 | Wistar Inst | Inhibidores del antigeno nuclear epstein-barr 1 (ebna1) y metodos que los utilizan. |
EP3793546A4 (en) | 2018-05-17 | 2021-12-08 | The Wistar Institute | CRYSTALLINE FORMS OF EBNA1-INHIBITOR AND METHOD OF MANUFACTURING AND USING THEREOF |
CN110423216B (zh) * | 2019-08-26 | 2021-01-05 | 浙江工业大学 | 一种2-(1-金刚烷甲酰胺基)乙基甲酸酯类化合物及其制备方法和应用 |
WO2024084056A1 (en) * | 2022-10-21 | 2024-04-25 | Etherna Immunotherapies Nv | Ionizable lipids |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2640055A (en) * | 1951-01-06 | 1953-05-26 | Warner Hudnut Inc | Amides |
CH500979A (de) * | 1967-02-16 | 1970-12-31 | Shimamoto Takio | Verfahren zur Herstellung von Pyridinmethylcarbamaten |
US3682922A (en) | 1969-01-16 | 1972-08-08 | Searle & Co | N-acyl-n-{8 (n{40 ,n{40 -disubstituted amino)-alkyl{9 -1-adamantylmethylamines |
US4724235A (en) | 1981-05-20 | 1988-02-09 | A. H. Robins Company, Incorporated | N-(arylthioalkyl)-N'-(aminoalkyl)ureas useful in the treatment of arrhythmia |
US4597902A (en) | 1981-05-20 | 1986-07-01 | A. H. Robins Company, Incorporated | N-(arylthioalkyl)-N'-(aminoalkyl)ureas |
US4555515A (en) * | 1985-02-25 | 1985-11-26 | Stauffer Chemical Co. | Pyridylpropyl carbamates as insect repellents |
US5599944A (en) * | 1987-03-24 | 1997-02-04 | Bayer Aktiengesellschaft | Intermediates for herbicidal sulphonylaminocarbonyltriazolinones having substituents which are bonded via sulphur |
US5776963A (en) * | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
FR2664269B1 (fr) | 1990-07-05 | 1992-10-02 | Roussel Uclaf | Nouveaux derives n-substitues d'alpha-mercapto alkylamines, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant. |
US5173506A (en) | 1990-08-16 | 1992-12-22 | Schering Corporation | N-(mercaptoalkyl)ureas and carbamates |
WO1992007567A1 (en) * | 1990-11-06 | 1992-05-14 | Smithkline Beecham Corporation | Imidazolidinone compounds |
NZ242054A (en) * | 1991-03-22 | 1993-11-25 | British Tech Group | Pyridine derivatives having a bridged alicyclic group; medicaments |
GB9401129D0 (en) | 1994-01-21 | 1994-03-16 | British Bio Technology | Hydroxamic acid derivatives as metalloproteinase inhibitors |
PT757685E (pt) * | 1994-04-29 | 2004-10-29 | Pfizer | Novas amidas ciclicas como incrementadores de libertacao de neurotransmissores |
AU6709596A (en) * | 1995-08-22 | 1997-03-19 | Japan Tobacco Inc. | Amide compounds and use of the same |
GB9526558D0 (en) * | 1995-12-27 | 1996-02-28 | Fujisawa Pharmaceutical Co | Heterobicyclic derivatives |
GB9526560D0 (en) * | 1995-12-27 | 1996-02-28 | Bayer Ag | Use of 2-Amino-Heterocycles |
EP0880511A4 (en) * | 1996-01-16 | 1999-06-16 | Merck & Co Inc | INTEGRIN RECEPTOR ANTAGONISTS |
IT1283637B1 (it) * | 1996-05-14 | 1998-04-23 | Italfarmaco Spa | Composti ad attivita' antinfiammatoria ed immunosoppressiva |
JP2001506257A (ja) | 1996-12-17 | 2001-05-15 | 藤沢薬品工業株式会社 | Mmpまたはtnf阻害剤としてのピペラジン化合物 |
DE59806420D1 (de) | 1997-09-17 | 2003-01-09 | Chemiefaser Lenzing Ag | Verfahren zur Behandlung von Cellulosefasern |
EP0903434B1 (de) * | 1997-09-17 | 2002-11-27 | Lenzing Aktiengesellschaft | Verfahren zur Behandlung von Cellulosefasern |
JP3603177B2 (ja) | 1998-03-26 | 2004-12-22 | 参天製薬株式会社 | 新規ウレア誘導体 |
WO1999050238A1 (fr) * | 1998-03-26 | 1999-10-07 | Santen Pharmaceutical Co., Ltd. | Nouveaux derives d'uree |
JP3472917B2 (ja) | 1998-08-05 | 2003-12-02 | 参天製薬株式会社 | 含窒素芳香族複素環を有する新規ウレア誘導体 |
KR100663143B1 (ko) | 1998-08-05 | 2007-01-02 | 산텐 세이야꾸 가부시키가이샤 | 질소 포함 방향족 헤테로고리를 갖는 신규 우레아 유도체 |
EP1165531A1 (en) * | 1999-03-19 | 2002-01-02 | Du Pont Pharmaceuticals Company | N-adamant-1-yl-n'- 4-chlorobenzothiazol-2-yl] urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent |
CA2369666A1 (en) * | 1999-04-07 | 2000-10-19 | Santen Pharmaceutical Co., Ltd. | N-substituted-n'-substituted urea derivatives and the use thereof as tnf-.alpha production inhibitory agents |
DE29910780U1 (de) * | 1999-06-21 | 1999-09-16 | Hahn Schickard Ges | Halte- und Betätigungsvorrichtung |
EP1743885B1 (en) * | 2000-05-31 | 2009-11-11 | Santen Pharmaceutical Co., Ltd. | 1-[(adamantyl)alkyl]-3-[(pyridinyl)alkyl]urea compounds as TNF-.alpha inhibitors useful for autoimmune diseases |
CA2468704C (en) | 2001-11-30 | 2011-06-14 | Santen Pharmaceutical Co., Ltd. | Urea derivatives as angiogenesis inhibitors |
-
2001
- 2001-05-31 EP EP06076696A patent/EP1743885B1/en not_active Expired - Lifetime
- 2001-05-31 CA CA2409741A patent/CA2409741C/en not_active Expired - Fee Related
- 2001-05-31 WO PCT/JP2001/004586 patent/WO2001092229A1/ja active IP Right Grant
- 2001-05-31 JP JP2001164523A patent/JP3867196B2/ja not_active Expired - Fee Related
- 2001-05-31 EP EP01934447A patent/EP1302461B1/en not_active Expired - Lifetime
- 2001-05-31 AT AT01934447T patent/ATE374186T1/de active
- 2001-05-31 KR KR1020087023872A patent/KR100978304B1/ko not_active IP Right Cessation
- 2001-05-31 EP EP05290274A patent/EP1568692B1/en not_active Expired - Lifetime
- 2001-05-31 CN CNB200410054677XA patent/CN1324012C/zh not_active Expired - Fee Related
- 2001-05-31 AU AU6067401A patent/AU6067401A/xx active Pending
- 2001-05-31 ES ES05290275T patent/ES2284138T3/es not_active Expired - Lifetime
- 2001-05-31 DE DE60130658T patent/DE60130658T2/de not_active Expired - Lifetime
- 2001-05-31 EP EP05290275A patent/EP1561749B1/en not_active Expired - Lifetime
- 2001-05-31 ES ES06076696T patent/ES2339141T3/es not_active Expired - Lifetime
- 2001-05-31 US US10/168,777 patent/US7098226B2/en not_active Expired - Fee Related
- 2001-05-31 KR KR1020027016230A patent/KR100880698B1/ko not_active IP Right Cessation
- 2001-05-31 ES ES05290274T patent/ES2353020T3/es not_active Expired - Lifetime
- 2001-05-31 DE DE60143098T patent/DE60143098D1/de not_active Expired - Lifetime
- 2001-05-31 ES ES01934447T patent/ES2293993T3/es not_active Expired - Lifetime
- 2001-05-31 PT PT01934447T patent/PT1302461E/pt unknown
- 2001-05-31 CN CNB2004100546746A patent/CN1307159C/zh not_active Expired - Fee Related
- 2001-05-31 DE DE60140495T patent/DE60140495D1/de not_active Expired - Lifetime
- 2001-05-31 DK DK01934447T patent/DK1302461T3/da active
- 2001-05-31 CN CNB018102336A patent/CN1284771C/zh not_active Expired - Fee Related
- 2001-05-31 AT AT05290275T patent/ATE358122T1/de not_active IP Right Cessation
- 2001-05-31 DE DE60127595T patent/DE60127595T2/de not_active Expired - Lifetime
- 2001-05-31 AT AT06076696T patent/ATE448204T1/de not_active IP Right Cessation
- 2001-05-31 AU AU2001260674A patent/AU2001260674B2/en not_active Ceased
- 2001-05-31 CA CA2736344A patent/CA2736344A1/en not_active Abandoned
- 2001-05-31 AT AT05290274T patent/ATE481385T1/de not_active IP Right Cessation
-
2002
- 2002-11-28 NO NO20025718A patent/NO324472B1/no not_active IP Right Cessation
-
2006
- 2006-02-28 AU AU2006200864A patent/AU2006200864B2/en not_active Ceased
- 2006-05-19 JP JP2006140241A patent/JP4482735B2/ja not_active Expired - Fee Related
- 2006-06-07 US US11/448,634 patent/US7491739B2/en not_active Expired - Fee Related
- 2006-06-22 US US11/472,603 patent/US7345064B2/en not_active Expired - Fee Related
-
2007
- 2007-06-29 NO NO20073371A patent/NO20073371L/no not_active Application Discontinuation
- 2007-08-15 US US11/893,238 patent/US20080182881A1/en not_active Abandoned
- 2007-12-14 CY CY20071101588T patent/CY1107089T1/el unknown
-
2009
- 2009-09-23 US US12/586,515 patent/US7923461B2/en not_active Expired - Fee Related
- 2009-12-14 JP JP2009283085A patent/JP2010059205A/ja active Pending
- 2009-12-14 JP JP2009283084A patent/JP2010059204A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002053555A5 (ja) | ||
JP2004512328A5 (ja) | ||
JP2006514626A5 (ja) | ||
JP2007016035A5 (ja) | ||
JP2004521087A5 (ja) | ||
WO2001062737A3 (en) | Amino pyrazole derivatives useful for the treatment of obesity and other disorders | |
EP1797881A4 (en) | MEDICAL COMPOSITION | |
JO2371B1 (en) | 4-phenyl-pyridine derivatives | |
JP2006526031A5 (ja) | ||
NO20081304L (no) | Form av 3-[(2{4-(heksyloksykarbonylamino-imino-metyl)-fenylamino]-metyl}-1-metyl-1H-benzimidazol-5-karbonyl)-pyridin-2-yl-amino]propionsyreetylester for oral administrering. | |
NO20071577L (no) | Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer | |
RS51477B (en) | SUBSTITUTED ALKYLAMINE DERIVATIVES AND PROCEDURES FOR THEIR USE | |
JP2004532209A5 (ja) | ||
JP2004506632A5 (ja) | ||
EP2039687A4 (en) | THERAPEUTIC OR PROPHYLACTIC AGENT AGAINST MULTIPLE SCLEROSIS | |
JP2005526081A5 (ja) | 代謝型グルタメート受容体−5の二アリール置換テトラゾールモジュレータ | |
WO2002015662A3 (en) | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists | |
EP1498411A4 (en) | DICETOHYDRAZINE DERIVATIVE COMPOUNDS AND MEDICAMENTS CONTAINING THESE COMPOUNDS AS ACTIVE INGREDIENTS | |
JP2006517939A5 (ja) | ||
JP2009504793A5 (ja) | ||
JP2010527993A5 (ja) | ||
JP2002030084A5 (ja) | ||
WO2001074791A1 (fr) | Derives de diazepane ou sels desdits composes | |
HK1097474A1 (en) | Carbostyril derivatives for accelerating salivation | |
JP2010511631A5 (ja) |